JOBEN BIO-MEDICAL CO., LTD.
🇨🇳China
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
Phase 2
- Conditions
- Radiodermatitis
- Interventions
- Drug: 3000 mg of PEG-400 per dayDrug: 2000 mg of JBM-TC4 per dayDrug: 3000 mg of JBM-TC4 per day
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Joben Bio-Medical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT02289365
- Locations
- 🇨🇳
Departmant of Radiotherapy, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan
🇨🇳Department of Oncology, Taipei Verterans General Hospital, Taipei, Taiwan
News
No news found